BioPharm International-09-01-2014

September 03, 2014

This article is the third and final in a series designed to offer leaders and managers at all levels in the industry a road map to excellence in human performance and human error prevention.

September 01, 2014

Chinese healthcare reforms may be a double-edged sword for foreign companies.

September 01, 2014

As the pharmacovigilance infrastructure becomes more entrenched in Europe, drug manufacturers are beginning to feel the burden of its high cost.

September 01, 2014

Annual study shows geographic proximity not a factor in CMO selection.

September 01, 2014

FDA demands accurate manufacturing and test information to ensure product quality.

September 01, 2014

Careful selection of downstream processing conditions is a must.

September 01, 2014

Vial adapters can reduce variation of volume withdrawn from injectable drug vials.

September 01, 2014

A well-constructed quality agreement can be an important tool to enable effective collaboration between owner and CMO.

September 01, 2014

Industry associations play a strong role in helping the pharmaceutical industry meet challenges.

September 01, 2014

Developing and maintaining a current master plan for cleaning in multi-product facilities are crucial.

September 01, 2014

Program review can help quality risk management live up to the promise of ICH Q9.

September 01, 2014

Experts discuss the future of modular manufacturing and the challenges that biopharma manufacturers face in facility design

September 01, 2014

Design space generation is encouraged in new product development.

September 01, 2014

Click the title above to open the BioPharm International September 2014 issue in an interactive PDF format.